A Human-First Discovery Approach: Leveraging Clinical Data to Identify Microbial Communities Driving Positive Clinical Outcomes

Time: 3:00 pm
day: Day Two – Track B – 2


  • Utilizing data from human microbiota transplantation studies and machine learning to develop novel investigational microbiome therapeutics and retire risk early
  • An update on Finch’s clinical and preclinical pipeline
  • An update on latest clinical data supporting Finch’s lead product candidate, CP101, for the prevention of recurrent C. difficile infection